Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

apixaban

Known as: 1H-Pyrazolo(3,4-c)pyridine-3-carboxamide, 4,5,6,7-tetrahydro-1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxo-1-piperidinyl)phenyl)-, apixabanum, apixabán 
An orally active inhibitor of coagulation factor Xa with anticoagulant activity. Apixaban directly inhibits factor Xa, thereby interfering with the… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
PURPOSE To provide updated recommendations about prophylaxis and treatment of venous thromboembolism (VTE) in patients with… Expand
Review
2019
Review
2019
Essentials We investigated direct oral anticoagulant (DOAC) use in venous thromboembolism and thrombophilia. A comprehensive… Expand
Review
2018
Review
2018
ABSTRACT The use of warfarin, the most commonly prescribed oral anticoagulant, is being questioned by clinicians worldwide due to… Expand
  • table 1
  • figure 1
  • table 2
  • table 4
  • table 5
Review
2018
Review
2018
BACKGROUND Direct oral anticoagulants (DOACs) are widely used for secondary prevention of venous thromboembolism (VTE) but their… Expand
Review
2018
Review
2018
Purpose of reviewDecision-making on resuming oral anticoagulant (OAC) after intracerebral hemorrhage (ICH) evokes significant… Expand
  • figure 1
Review
2017
Review
2017
Direct oral anticoagulants (DOACs) are recognized by evidence-based treatment guidelines as the first-line option for the… Expand
  • table 2
  • table 3
  • table 5
  • table 6
Highly Cited
2013
Highly Cited
2013
BACKGROUND Apixaban, an oral factor Xa inhibitor administered in fixed doses, may simplify the treatment of venous… Expand
  • figure 1
  • table 1
  • table 1
  • table 2
  • table 2
Highly Cited
2011
Highly Cited
2011
BACKGROUND Vitamin K antagonists are highly effective in preventing stroke in patients with atrial fibrillation but have several… Expand
  • table 1
  • table 1
  • table 2
  • figure 1
  • table 3
Highly Cited
2011
Highly Cited
2011
BACKGROUND Vitamin K antagonists have been shown to prevent stroke in patients with atrial fibrillation. However, many patients… Expand
  • table 1
  • table 1
  • table 2
  • table 3
  • figure 1
Highly Cited
2011
Highly Cited
2011
BACKGROUND Apixaban, an oral, direct factor Xa inhibitor, may reduce the risk of recurrent ischemic events when added to… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2